What is VRCA's current stock price?

VRCA (Verrica Pharmaceuticals Inc.) is currently trading at $6.06 with a market cap of $64.5M.

What sector is Verrica Pharmaceuticals Inc. in?

Verrica Pharmaceuticals Inc. (VRCA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is VRCA a good stock to buy?

Analysts have a Buy consensus on VRCA with a price target of $17.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

VRCA Verrica Pharmaceuticals Inc.

Healthcare

$6.06+2.71%ClosedMarket Cap: $64.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.02

P/S

1.74

EV/EBITDA

-3.93

DCF Value

$-21.84

FCF Yield

-21.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

89.5%

Operating Margin

-36.4%

Net Margin

-48.0%

ROE

-1136.5%

ROA

-46.0%

ROIC

-58.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$5.0M	$-9.7M	$—
Q4 null	$5.1M	$-8.1M	$—
FY null	$35.6M	$-17.9M	$—
Q3 null	$14.3M	$-274.0K	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.00

Target (Median)

$17.00

Target Range

$17.00 - $17.00

0 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Brookline CapitalBuy

2025-12-18

Trading Activity

Insider Trades

View All

BKB Growth Investments, LLC10 percent owner

SellMon Feb 02

BKB Growth Investments, LLC10 percent owner

SellMon Jan 26

BKB Growth Investments, LLC10 percent owner

SellMon Jan 26

BKB Growth Investments, LLC10 percent owner

SellMon Jan 26

Kirby John J.officer: Interim CFO

SellTue Dec 30

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.55

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Peers